Key facts: NASDAQ:ARQT Starts Phase 3 Trial; Target Rises to $39.62

Arcutis Biotherapeutics (ARQT) began a Phase 3 trial for its ZORYVE cream to treat atopic dermatitis. The company's average 12-month price target increased to $39.62, suggesting 16% upside from its Nov. 4 close, with seven Buy and one Hold ratings.

Original reporting
Published Nov 6, 2026, 8:00 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 6, 2026, 9:04 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Key facts: NASDAQ:ARQT Starts Phase 3 Trial; Target Rises to $39.62 — source image
Decision brief

The 30-second read

$ARQTBullishMed
01

Why it matters

The enrollment milestone validates the development program and may trigger short-term buying pressure.

02

Market read

First Phase 3 enrollment is a primary catalyst for ARQT, potentially driving short-term price appreciation.

03

What to watch

Regulatory timeline and enrollment speed could delay data readout.

Relevance 8/10Novelty 8/10Timing: pre-market today

Background

Arcutis Biotherapeutics announced first patient enrollment in its Phase 3 trial for ZORYVE cream targeting atopic dermatitis.

Company-level read

Ticker impact

$ARQTBullishHigh confidence
Context

First enrollment in Phase 3 INTEGUMENT-3 trial and analyst price target raised to $39.62.

Expected impact

likely upward pressure as investors price in trial progress

Evidence & confidence

Phase 3 start is a material catalyst for a biotech; target raise indicates analyst optimism.

Market effects

May lift other atopic dermatitis biotech peers.

Limited to US biotech sector.

Low global impact beyond biotech investors.

Counterpoint

Trial could face setbacks; price target may be premature.

Key entities

  • Arcutis Biotherapeutics

    NASDAQ-listed biotech developing ZORYVE cream.

Related articles

$ARQTHighAI 8/10

Arcutis reports trial data on infant eczema treatment candidate

Arcutis Biotherapeutics (ARQT) presented INTEGUMENT-INFANT trial data for ZORYVE cream 0.05% in treating infant atopic dermatitis. The study showed no serious adverse events, with 66.7% of infants reporting itch improvement within 4 hours. The cream is approved for children 2-5 years and is under FDA review for infants 3-24 months, with a decision expected by February 23, 2027.

$ARQTMed

Arcutis (ARQT) Q3 2026 Earnings Call Transcript

Arcutis Biotherapeutics (ARQT) reported Q3 2026 revenue of $143.9M, up 45% YoY, driven by ZORYVE franchise growth. Full-year revenue guidance raised to $535M-$545M. Net income was $8.8M, with cash and securities at $259.8M. The company plans to invest in commercial initiatives for 2027 growth, focusing on dermatology and primary care.

$ARQTMedAI 8/10

TD Cowen raises Arcutis stock price target on Zoryve momentum

TD Cowen raised its price target for Arcutis Biotherapeutics (ARQT) to $40 from $35, citing strong Zoryve sales of $144M and raised 2026 guidance. Revenue grew 11% quarter-over-quarter and 45% year-over-year, with a 91% gross profit margin. The stock trades near its 52-week high at $34.05. Arcutis reported Q3 2026 revenue of $143.9M, beating estimates, but missed profit expectations.